Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...

Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. They not only infect and kill cancer cells, but also modulate the tumor micro-environment to enhance ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

Roche has shared updated findings from the global Phase III SKYSCRAPER-01 study, a critical investigation into the efficacy of combining tiragolumab with Tecentriq® (atezolizumab) for treating ...

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we explore the ...

The US Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), the first gene therapy for children with metachromatic leukodystrophy (MLD). This one-time treatment ...

Presented at the 2025 SABCS annual meeting, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease recurrence or death by 30% in early-stage ER-positive ...

Merck has launched construction of a $1 billion biologics facility in Wilmington, Delaware, set to become the U.S. production hub for KEYTRUDA and next-generation therapies such as ADCs. The ...

Ariceum Therapeutics announced that the US FDA has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial of its proprietary radiolabelled peptide, 225Ac-SSO110 ...

Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based therapy for Hepatocellular carcinoma. RZ-001 employs advanced RNA editing to target and suppress cancer growth, showing ...